Ole Munk

Mar 5, 2024 | ejnmmires.springeropen.com | Kim Vang |Anna Lyhne |Mette Pedersen |Ole Munk |André H. Dias |Anna Johnsson | +10 more

The protocol received approval from the Danish Medicines Agency (2019083844) and Central Denmark Region Committees on Health Research Ethics (1-10-72-195-19). The study is registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT: 2019-002665-35). The study was monitored by the Good Clinical Practice unit at Aarhus and Aalborg University Hospitals. Written and oral informed consent from all participating individuals were obtained.

Nov 30, 2023 | ejnmmires.springeropen.com | Paul Joseph Cumming |André H. Dias |Lars C. Gormsen |Allan K Hansen |Ian Alberts |Axel Rominger | +1 more

The Aarhus study was a retrospective evaluation of prospectively collected clinical FDG PET/CT data, approved by the local ethics committee of the Central Denmark Region (1-10-72-188-19). Inclusion into the dynamic whole-body (D-WB) protocol was solely based on whether patients were deemed fit to lie still for nearly 70 min while in the PET/CT scanner; in practice, this excluded patients with cognitive impairments.

Apr 15, 2023 | ejnmmires.springeropen.com | André H. Dias |Mads Jochumsen |Helle D. Zacho |Ole Munk |Lars C. Gormsen

Patient populationThis study was a retrospective analysis of data. Participants were recruited from all patients referred for PSMA PET/CT as part of their clinical evaluation if they were deemed fit to lie still for 70 min during scanning. The study was approved by the local ethics committee in the Central Denmark Region (1-10-72-188-19). D-WB PSMA data were obtained from 20 male patients with known prostate cancer.